Immunology for Pharmacy

Immunology for Pharmacy

Volumn , Issue , 2012, Pages

  Flaherty, Dennis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013709187     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2009-0-40304-0     Document Type: Book

References (353)

1. Anderson S.J., Perlmutter R.M. A signaling pathway governing early thymocyte maturation. Immunol Today 1995, 16:99.
2. Craig S.W., Cebra J.J. Peyer's patches: An enriched source of precursors for IgA producing immunocytes in the rat. J Exp Med 1971, 134:188.
3. Geissmann F., Manz M.G., Jung S., et al. Evolving views on the genealogy of B cells. Nat Rev Immunol 2008, 8(2):95.
4. Girard J.P., Springer T.A. High endothelial venules (HEVs): Specialized endothelium for lymphocyte migration. Immunol Today 1995, 16:449.
5. Kroese F.G.M., Timens W., Nieuwenhuis P. Germinal center reaction and B lymphocytes: Morphology and function 1990, Springer Verlag, Berlin.
6. Laman J.D., Van den Eertwegh A.J.M., Claassen E., et al. Cell-cell interactions: In situ studies of splenic humoral responses. Immune system accessory cells 1992, CRC Press, Boca Raton. L. Fornusek, V. Veivicka (Eds.).
7. Pawlowski T.J., Staerz U.E. Thymic education-T cells do it for themselves. Immunol Today 1994, 15:205-208.
8. Szakal A.K., Kosco M.H., Tew J.G. Microanatomy of lymphoid tissue during a humoral immune response: Structure function relationships. Annu Rev Immunol 1989, 7:91-109.
9. Webster A.D.B. Laboratory investigations of primary deficiencies of the lymphoid system. Clin Allergy Immunol 1985, 5:447-467.
10. Baumann H., Gauldie J. The acute phase response. Immunol Today 1994, 15(2):74.
11. Hoppe H.J., Reid K.B. Collectins-soluble proteins containing collagenous regions and lectin domains and their roles in innate immunity. Protein Sci 1994, 3:1143.
12. Kagan B.L., Ganz T., Lehrer R.I. Defensins: A family of antimicrobial and cytotoxic peptides. Toxicology 1994, 87:131.
13. Malhotra R., Merry T., Ray K.P. Innate immunity: A primitive system in humans,. Immunol Today 2000, 21(11):534.
14. Turner M.W. Mannose-binding lectin: The pluripotent molecule of the innate immune system. Immunol Today 1996, 17(11):532.
15. Benacerraf B., Paul W.E., Green I. Hapten-carrier relationships. Ann N Y Acad Sci 1970, 169(1):93.
16. Benjamin D., Berzofsky J., East I. The antigenic structure of proteins: A reappraisal. Annu Rev Immunol 1984, 2:67.
17. Smerdou C., Anton I.M., Plana J., et al. A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated Salmonella induces serum and secretory immunity. Virus Res 1996, 41:1.
18. Bjorkman P.J., Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990, 59:253.
19. Bjorkman P.J., Saper M.A., Samraoui B., et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987, 329(6139):512.
20. Brown J.H., Jardetzky T., Saper M.A., et al. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 1988, 332(6167):845.
21. Brown J.H., Jardetzky T.S., Gorga J.C., et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1988, 364(6432):33.
22. Diepolder H.M., Jung M.C., Keller E., et al. A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol 1998, 113(2):244.
23. Fairhurst R.M., Wang C.X., Sieling P.A., et al. CD1-restricted T cells and resistance to polysaccharide-encapsulated bacteria. Immunol Today 1998, 19(6):257.
24. Mehra N.K., Rajalingam R., Mitra D.K., et al. Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Int J Lepr Other Mycobact Dis 1995, 63(2):241.
25. Porcelli S.A., Segelke B.W., Sugita M., et al. The CD1 family of lipid antigen-presenting molecules. Immunol Today 1998, 19(8):362.
26. Stern L.J., Brown J.H., Jardetzky T.S., et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368(6468):215.
27. Touraine J.L. The bare lymphocyte syndrome. Combined immune deficiency by absence of HLA antigen expression. Presse Med 1984, 13(11):671.
28. Wang J.H., Meijers R., Xiong Y., et al. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc Natl Acad Sci U S A 2001, 98(19):10799.
29. Zeng Z., Castaño A.R., Segelke B.W., et al. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 1997, 277(5324):339.
30. Bénaroch P., Yilla M., Raposo G., et al. How MHC class II molecules reach the endocytic pathway. EMBO J 1995, 14(1):37.
31. Bieber T. The Langerhans cell: Outpost of the immune system in the epidermis. Hautarzt 1986, 37:424.
32. Gray D., Kosco M., Stockinger B. Novel pathways of antigen presentation for the maintenance of memory. Int Immunol 1991, 3:141.
33. Hart D.N., McKenzie J.L. Interstitial dendritic cells. Int Rev Immunol 1990, 6(2-3):127.
34. He X.Z., Wang L., Zhang Y.Y., et al. An effective vaccine against colon cancer in mice: Use of recombinant adenovirus interleukin-12 transduced dendritic cells. World J Gastroenterol 2008, 14(4):532.
35. Hsiao L., Takahashi K., Takeya M., et al. Differentiation and maturation of macrophages into interdigitating cells and their multicellular complex formation in the fetal and postnatal rat thymus. Thymus 1991, 17:219.
36. Morisaki T., Matsumoto K., Onishi H., et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 2003, 16(4):175.
37. Nestle F.O., Turka L.A., Nicoloff B.J. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994, 94(1):202.
38. Nonn M., Schinz M., Zumback K., et al. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol 2003, 129(9):511.
39. Parmentier H.K., van der Linden J.A., Krijnen J., et al. Human follicular dendritic cells: Isolation and characteristics in situ and in suspension. Scand J Immunol 1991, 33:441.
40. Szakal A.K., Kosco M.H., Tew J.G. A novel in vivo follicular dendritic cell-dependent iccosome-mediated mechanism for delivery of antigen to antigen-processing cells. J Immunol 1988, 140:341.
41. Tew J.G., Wu J., Qin D., et al. Follicular dendritic cells and presentation of antigen and co-stimulatory signals to B cells. Immunol Rev 1997, 156:39.
42. Villadangos J.A., Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008, 29(3):352.
43. Altmann A., Mustelin T., Coggeshall K.M., et al. T lymphocyte activation: A biological model of signal transduction. Crit Rev Immunol 1990, 10:348.
44. Anderson M.E., Siahaan T.J. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: Designing peptide and small molecule inhibitors. Peptides 2003, 24(3):487.
45. Brady R.L., Barclay A.N. The structure of CD4. Curr Top Microbiol 1996, 205:1.
46. Brenner M.B., McLean J., Dialynas D.P., et al. Identification of a putative second T cell receptor. Nature 1986, 322(6075):145.
47. Chien Y.H., Jores R., Crowley M.P., et al. Recognition by ?/? T cells. Annu Rev Immunol 1996, 14:511.
48. Damle N.K., Linsley P.S., Ledbetter J.A., et al. Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7. Eur J Immunol 1991, 21(5):1277.
49. Davis M.M., Bjorkman P.J. T cell antigen receptor genes and T cell recognition. Nature 1988, 334(6181):395.
50. DeLibero G. Sentinel function of broadly reactive human ?/? T cells. Immunol Today 1997, 22:22.
51. Engel I., Letourneur F., Houston J.T., Ottenhoff T.H., Klausner R.D. T cell receptor structure and function: Analysis by expression of portions of isolated subunits. Adv Exper Med Biol 1992, 323:1.
52. Garcia K.C., Degano M., Stanfield R.L., et al. An ?/? T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 1996, 274(5285):209.
53. Garcia K.C., Teyton L., Wilson I.A., et al. Structural basis of T cell recognition. Annu Rev Immunol 1999, 17:369.
54. Gollob J.A., Li J., Kawasaki H., et al. Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. J Immunol 157(5) 1886, 1996.
55. Gollob J.A., Ritz J. CD2-CD58 interaction and the control of T cell interleukin-12 responsiveness. Adhesion molecules link innate and acquired immunity. Ann NY Acad Sci 1996, 795:71.
56. Haas W., Pereira P., Tonegawa S., et al. ?/? cells. Annu Rev Immunol 1993, 11:637.
57. Harrison S.C., Wang J., Yan Y., et al. Structure and interactions of CD4. Cold Spring Harb Symp Quant Biol 1992, 57:541.
58. June C.H., Bluestone J.A., Nadler L.M., et al. The B7 and CD28 receptor families. Immunol Today 1994, 15:321.
59. Kehry M.R. CD40-mediated signaling in B cells. J Immunol 1996, 156:2345.
60. Leahy D.J. A structural view of CD4 and CD8. FASEB J 1995, 9:17.
61. Panina-Bordignon P., Fu X.T., Lanzavecchia A., et al. Identification of HLA-DR ?-chain residues critical for binding of the toxic shock syndrome toxin superantigen. J Exp Med 1992, 176(6):1779.
62. Raulet D.H. T-cell immunity. How ?/? T cells make a living. Curr Biol 1994, 4(3):246.
63. San José E., Sahuquillo A.G., Bragado R., et al. Assembly of the TCR/CD3 complex: CD3 ?/? and CD3 ?/? dimers associate indistinctly with both TCR ? and TCR ?-chains. Evidence for a double TCR heterodimer model. Eur J Immunol 1998, 28(1):12.
64. Stuber E., Strober W., Neurath M., et al. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med 1996, 183(2):693.
65. van der Merwe P.A., Barclay A.N., Mason D.W., et al. Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. Biochemistry 1994, 33(33):10149.
66. Zimmerman T., Blanco F.J. Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: Design and mechanism of action. Curr Pharm Des 2008, 14(22):2128.
67. Zumla A., Superantigens T cells, and microbes. Clin Infect Dis 1992, 15:313.
68. Bonnevier J.L., Mueller D.L. Cutting edge: B7/CD28 interactions regulate cell cycle progression independent of the strength of TCR signaling. J Immunol 2002, 169(12):6659.
69. Brini A.T., Harel-Bellan A., et al. Cyclosporin A inhibits induction of IL-2 receptor alpha chain expression by affecting activation of NF-?B-like factor(s) in cultured human T lymphocytes. Eur Cytokine Netw 1990, 1(3):131.
70. Buss W.C., Stepanek J., et al. Proposed mechanism of cyclosporine toxicity: inhibition of protein synthesis. Transplant Proc 1988, 20(Suppl 3):863.
71. Davis D.M., Dustin M.L. What is the importance of the immunological synapse?. Trends Immunol 2004, 25(6):323.
72. Gallo E.M., Cante-Barrett K., Crabree G.R., et al. Lymphocyte calcium signaling from membrane to nucleus. Nat Immunol 2006, 7(1):25.
73. Hogan P.G., Chen L., Nardone J., Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003, 17(18):2205.
74. Kuhns M.S., Davis M.M., Garcia K.C., et al. Deconstructing the form and function of the TCR/CD3 complex. Immunity 2006, 24(2):133.
75. Li Y., Sedwick C.E., Hu J., Altman A., et al. Role for protein kinase Ctheta (PKCtheta) in TCR/CD28-mediated signaling through the canonical but not the non-canonical pathway for NF-?B activation. J Biol Chem 2005, 280(2):1217.
76. Nelson B.H., Willerford D.M. Biology of the interleukin-2 receptor. Adv Immunol 1998, 70:1.
77. Oum J.H., Han J., Myung H., Hleb M., Sharma S., Park J. Molecular mechanism of NFAT family proteins for differential regulation of the IL-2 and TNF-alpha promoters. Mol Cells 2002, 13(1):77.
78. Paliogianni F., Raptis A., Ahuja S.S., et al. Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 1993, 91(4):1481.
79. Palmer B.F., Toto R.D. Severe neurologic toxicity induced by cyclosporine A in three renal transplant patients. Am J Kidney Dis 1991, 18(1):116.
80. Rudolph M.G., Stanfield R.L., Wilson I.A. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006, 24:419.
81. Samelson L.E. Signal transduction mediated by the T cell antigen receptor: The role of adapter proteins. Annu Rev Immunol 2002, 20:371.
82. Sugamura K., Asao H., Kondo M., et al. The interleukin-2 receptor gamma chain: Its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 1996, 14:179.
83. Thomson A.W., Whiting P.H., Simpson J.G. Cyclosporine: Immunology, toxicity and pharmacology in experimental animals. Agents Actions 1984, 15(3-4):306.
84. Weil R., Israel A. Deciphering the pathway from the TCR to NF-?B. Cell Death Differ 2006, 13(5):826.
85. Aruffo A., Kanner S.B., Sgroi D., et al. CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signaling. Proc Natl Acad Sci U S A 1992, 89(21):10242.
86. Cherukuri A., Carter R.H., Brooks S., et al. B cell signaling is regulated by induced palmitoylation of CD81. J Biol Chem 2004, 279(30):31973.
87. Cherukuri A., Cheng P.C., Sohn H.W., et al. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 2001, 14(2):169.
88. Dall'Era M., Chakravarty E., Wallace D., et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56(12):4142.
89. Ettinger R., Sims G.P., Robbins R., et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007, 178(5):2872.
90. Gross J.A., Dillon S.R., Mudri S., et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15(2):289.
91. Hartung H.P. Atacicept: A new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt 2009, 80(12):1462.
92. Kawasaki A., Tsuchiya N., Fukazawa T., et al. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002, 3(7):424.
93. Otipoby K.L., Andersson K.B., Draves K.E., et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 1996, 384(6610):634.
94. Pleiman C.M., D'Ambrosio D., Cambier J.C., et al. The B-cell antigen receptor complex: Structure and signal transduction. Immunol Today 1994, 15(9):393.
95. Quartuccio L., Fabris M., Ferraccioli G. B lymphocyte stimulator (BLyS) and monocytes: Possible role in autoimmune diseases with a particular reference to rheumatoid arthritis. Reumatismo 2004, 56(3):143.
96. Rolli V., Gallwitz M., Wossning T., et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol Cell 2002, 10(5):1057.
97. Smith K.G., Fearon D.T. Receptor modulators of B-cell receptor signalling-CD19/CD22. Curr Top Microbiol Immunol 2000, 245(1):195.
98. Snapper C.M., Mond J.J. A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J Immunol 1996, 157(6):2229.
99. Stein K.E. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992, 1651(Suppl):S49.
100. Vugmeyster Y., Seshasayee D., Chang W., et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol 2006, 168(2):476.
101. Wang X., Huang W., Schiffer L.E., et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003, 48(2):495.
102. Weng W.K., Jarvis L., LeBien T.W. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. J Biol Chem 1994, 269(51):32514.
103. Zanetti M., Glotz D. Considerations on thymus-dependent and -independent antigens in acquired and natural immunity. Ann Inst Pasteur Immunol 1988, 139(2):192.
104. Almogren A.B., Senior W., Loomes L.M., et al. Structural and functional consequences of cleavage of human secretory and human serum immunoglobulin A1 by proteinases from Proteus mirabilis and Neisseria meningitidis. Infect Immun 2003, 71(6):3349.
105. Bjornson A.B., Detmers P.A. The pentameric structure of IgM is necessary to enhance opsonization of Bacteroides thetaiotaomicron and Bacteroides fragilis via the alternative complement pathway. Microb Pathog 1995, 19(2):117.
106. Brewer J.W., Corley R.B. Late events in assembly determine the polymeric structure and biological activity of secretory IgM. Mol Immunol 1997, 34(4):323.
107. Burton D.R., Woof J.M. Human antibody effector function. Adv Immunol 1992, 51:1.
108. Fallgreen-Gebauer E., Gebauer W., Bastian A., et al. The covalent linkage of secretory component to IgA. Structure of sIgA. Biol Chem Hoppe Seyler 1993, 374(11):1023.
109. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review. Leukemia 2009, 23(12):2210.
110. Gotz H., Kirschbaum R. Immunoglobulins gamma D (IgD) and gamma E (IgE). Structure, function and clinical importance [translation]. Med Klin 1971, 66(51):1749.
111. Gould H.J., Sutton B.J., Beavil A.J., et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003, 21:579.
112. Harris L.J., Larson S.B., MacPherson A. Comparison of intact antibody structures and the implications for effector function. Adv Immunol 1999, 72:191.
113. Krivan G., Gacs G., et al. Hyperimmunoglobulinemia E (Job) syndrome [translation]. Orv Hetil 1991, 132(7):369.
114. Porter R.R. Separation and isolation of fractions of rabbit gamma-globulin containing the antibody and antigenic combining sites. Nature 1958, 182(4636):670.
115. Schur P.H. IgG subclasses-a review. Ann Allergy 1987, 58(2):89-96. 99.
116. Shakib F., Stanworth D.R. Human IgG subclasses in health and disease. (A review). Part II. Ric Clin Lab 1980, 10(4):561.
117. Burton D.R., Woof J.M. Human antibody effector function. Adv Immunol 1992, 51:1.
118. Early P., Hood L. Allelic exclusion and nonproductive immunoglobulin gene rearrangements. Cell 1981, 24(1):1.
119. Gould H.J., Sutton B.J., Beavil A.J., et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003, 21:579.
120. Jeske D.J., Jarvis J., Milstein C., et al. Junctional diversity is essential to antibody activity. J Immunol 1984, 133(3):1090.
121. Jung D., Alt F.W. Unraveling V(D)J recombination: Insights into gene regulation. Cell 2004, 116(2):299.
122. Kalmanovich G., Mehr R. Models for antigen receptor gene rearrangement. III. Heavy and light chain allelic exclusion. J Immunol 2003, 170(1):182.
123. Komori T., Sugiyama H. N sequences, P nucleotides and short sequence homologies at junctional sites in VH to VHDJH and VHDJH to JH joining. Mol Immunol 1993, 30(16):1393.
124. Lewis S.M. P nucleotides, hairpin DNA and V(D)J joining: Making the connection. Semin Immunol 1994, 6(3):131.
125. Meier J.T., Lewis S.M. P nucleotides in V(D)J recombination: A fine-structure analysis. Mol Cell Biol 1993, 13(2):1078.
126. Milstein C. Affinity maturation of antibodies. Immunol Today 1991, 12(2):93.
127. Schmale J., Costea N., Dray S., et al. Allelic exclusion of light chain allotypes in rabbit IgM cold agglutinins. Proc Soc Exp Biol Med 1969, 130(1):48-50.
128. Carroll M.C. The complement system in regulation of adaptive immunity. Nat Immunol 2004, 5(10):981.
129. Carroll M.C. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998, 16:545.
130. Chaplin H. Review: The burgeoning history of the complement system 1888-2005. Immunohematology 2005, 21(3):85.
131. Colten H.R., Rosen F.S. Complement deficiencies. Annu Rev Immunol 1992, 10:809.
132. Davitz M.A. Decay-accelerating factor (DAF): A review of its function and structure. Acta Med Scand Suppl 1987, 715:111.
133. Gotze O., Muller-Eberhard H.J. The C3-activator system: An alternate pathway of complement activation. J Exp Med 1971, 134(3 Pt 2):90s.
134. Jasin H.E. Human heat labile opsonins: Evidence for their mediation via the alternate pathway of complement activation. J Immunol 1972, 109(1):26.
135. Liszewski M.K., Farries T.C., Lublin D.M., et al. Control of the complement system. Adv Immunol 1996, 61:201.
136. Loos M. Bacteria and complement-a historical review. Curr Top Microbiol Immunol 1985, 121:1.
137. Pickering M.C., Cook H.T. Translational mini-review series on complement factor H: Renal diseases associated with complement factor H: Novel insights from humans and animals. Clin Exp Immunol 2008, 151(2):210.
138. Roozendaal R., Carroll M.C. Emerging patterns in complement-mediated pathogen recognition. Cell 2006, 125(1):29.
139. Thurman J.M., Holers V.M. The central role of the alternative complement pathway in human disease. J Immunol 2006, 176(3):1305.
140. Sahu A., Sunyer J.O., Moore W.T., et al. Structure, functions, and evolution of the third complement component and viral molecular mimicry. Immunol Res 1998, 17(1-2):109.
141. Sunyer J.O., Zarkadis I.K., Lambris J.D. Complement diversity: A mechanism for generating immune diversity?. Immunol Today 1998, 19(11):519.
142. Walport M.J. Complement. First of two parts. N Engl J Med 2001, 344(14):1058.
143. Walport M.J. Complement. Second of two parts. N Engl J Med 2001, 344(15):1140.
144. Campo López C., Calabuig Alborch J.R., Aguilar Jiménez J., et al. Skeletal manifestations of Gauchers disease: A report of two cases. An Med Interna 2004, 21(4):179.
145. Cech P., Papathanassiou A., Boreux G., et al. Hereditary myeloperoxidase deficiency. Blood 1979, 53(3):403.
146. Cech P., Stalder H., Widmann J.J., et al. Leukocyte myeloperoxidase deficiency and diabetes mellitus associated with Candida albicans liver abscess. Am J Med 1979, 66(1):149.
147. Gresham H.D., McGarr J.A., Shackelford P.G., et al. Studies on the molecular mechanisms of human Fc receptor-mediated phagocytosis. Amplification of ingestion is dependent on the generation of reactive oxygen metabolites and is deficient in polymorphonuclear leukocytes from patients with chronic granulomatous disease. J Clin Invest 1988, 82(4):1192.
148. Karnovsky M.L., Badwey J.A. Respiratory burst during phagocytosis: An overview. Methods Enzymol 1986, 132:353.
149. Koppenol W.H., Butler J. Mechanism of reactions involving singlet oxygen and the superoxide anion. FEBS Lett 1977, 83(1):1.
150. Wolf J.E., Ebel L.K. Chronic granulomatous disease: Report of case and review of the literature. J Am Dent Assoc 1978, 96(2):292.
151. Anderson M.J., Woods V.L., Tani P., et al. Autoantibodies to platelet glycoprotein IIb/IIIa and to the acetylcholine receptor in a patient with chronic idiopathic thrombocytopenic purpura and myasthenia gravis. Ann Intern Med 1984, 100(6):829.
152. Ashrafi A.H., Wang J., Stockwell C.A., et al. Kawasaki disease: Four case reports of cardiopathy with an institutional and literature review. Pediatr Dev Pathol 2007, 10(6):491.
153. Billetta R., Lobuglio A.F. Chimeric antibodies. Int Rev Immunol 1993, 10(2-3):165.
154. Callahan C.W., Musci M.N., Santucci T.F., et al. Cefaclor serum sickness-like reactions: Report of a case and review of the literature. J Am Osteopath Assoc 1985, 85(7):450.
155. Fengtian H., Yongzhan N., Baojun C., et al. Production of phage-displayed anti-idiotypic antibody single chain variable fragments to MG7 monoclonal antibody directed against gastric carcinoma. Chin Med Sci J 2002, 17(4):215.
156. Kaplan C. Diopathic thrombocytopenic purpura, autoantibodies, autoantigens. An overview. Ann Med Interne (Paris) 1992, 143(6):371.
157. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495.
158. Kontermann R.E., Volkel T., Korn T. Production of recombinant bispecific antibodies. Methods Mol Biol 2004, 248:227.
159. Lewis A.P., Crowe J.S. Generation of humanized monoclonal antibodies by "best fit" framework selection and recombinant polymerase chain reaction. Year Immunol 1993, 7:110.
160. Nolan O., O'Kennedy R. Bifunctional antibodies: Concept, production and applications. Biochim Biophys Acta 1990, 1040(1):1.
161. Bene M.C., Kolopp Sarda M.N., El Kaissauni J., et al. Automated cell count in flow cytometry: A valuable tool to assess CD4 absolute levels in peripheral blood. Am J Clin Pathol 1998, 110(3):321.
162. Burshtyn D.N., Davidson C. Natural killer cell conjugate assay using two-color flow cytometry. Methods Mol Biol 2010, 612:89.
163. Duque R.E., Andreeff M., Braylan R.C., et al. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993, 14(5):492.
164. Hengel R.L., Nicholson J.K. An update on the use of flow cytometry in HIV infection and AIDS. Clin Lab Med 2001, 21(4):841.
165. Lau L.G., Tan G.B., Kuperan B. CD4 lymphocyte enumeration in patients with human immunodeficiency virus infection using three-colour and four-colour dual-platform flow cytometry: An inter-laboratory comparative evaluation. Ann Acad Med Singapore 2002, 31(6):765.
166. Subira D., Gorgolas M., Castañón S., et al. Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med 2005, 6(1):21.
167. Weisberger J., Wu C.D., Liu Z., et al. Differential diagnosis of malignant lymphomas and related disorders by specific pattern of expression of immunophenotypic markers revealed by multiparameter flow cytometry (Review). Int J Oncol 2000, 17(6):1165.
168. Al-Shemari H., Bosse Y., Hudson T.J., et al. Influence of leukotriene gene polymorphisms on chronic rhinosinusitis. BMC Med Genet 2008, 9:21.
169. Anderson S.D., Daviskas E. The mechanism of exercise-induced asthma. J Allergy Clin Immunol 2000, 106(3):453.
170. Blumenthal M.N. The role of genetics in the development of asthma and atopy. Curr Opin Allergy Clin Immunol 2005, 5(2):141.
171. Coyle A.J., Wagner K., Bertrand C., et al. Central role of immunoglobulin (Ig)E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: Inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996, 183(4):1303.
172. Enrique E. Immunotherapy in the treatment of food allergy. Does it have a future?. Allergol Immunopathol (Madr) 2009, 37(3):143.
173. Gould H.J., Sutton B.J., Beavil A.J., et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003, 21:579.
174. Kay A.B. Allergy and allergic diseases. Second of two parts. N Engl J Med 2001, 344(2):109.
175. Litonjua A.A., Lasky-Su J., Schneiter K., et al. ARG1 is a novel bronchodilator response gene: Screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008, 178(7):688.
176. Maddox L., Schwartz D.A. The pathophysiology of asthma. Annu Rev Med 2002, 53:477.
177. Ono S.J. Molecular genetics of allergic diseases. Annu Rev Immunol 2000, 18:347.
178. Suzuki Y., Ra C. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: Aspirin modulation of IgE-dependent mast cell activation: role of aspirin-induced exacerbation of immediate allergy. J Pharmacol Sci 2009, 110(3):237.
179. Togo K., Suzuki Y., Yoshimaru T., et al. Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydropyridine receptor-mediated Ca(2+) influx. Clin Immunol 2009, 131(1):145.
180. Wild L.G., Lehrer S.B. Immunotherapy for food allergy. Curr Allergy Rep 2000, 1(1):48.
181. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349(16):1526.
182. Bach J.F. Infections and autoimmune diseases. J Autoimmun 2005, 25(Suppl):74.
183. Bahn R.S. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab 1939, 88(5):2003.
184. Burke W.J. Myasthenia gravis: A clinical review,. Clin Exp Neurol 1981, 17:1.
185. Davidson A., Diamond B. Autoimmune diseases. N Engl J Med 2001, 345(5):340.
186. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350(25):2572.
187. Maxfield D.L., Boyd W.C. Pernicious anemia: A review, an update, and an illustrative case,. J Am Osteopath Assoc 1983, 83(2):133.
188. Mazzaferri E.L., Skillman T.G. Thyroid storm. A review of 22 episodes with special emphasis on the use of guanethidine,. Arch Intern Med 1969, 124(6):684.
189. McKenzie J.M. Review: Pathogenesis of Graves' Disease: Role of the long-acting thyroid stimulator. J Clin Endocrinol Metab 1965, 25:424.
190. Spesivtseva V.G. Etiology, pathogenesis, and diagnosis of diffuse toxic goiter and Hashimoto's thyroiditis [translation]. Ter Arkh 1981, 53(10):147.
191. Von Herrath M.G., Fujinami R.S., Whitton J.L. Microorganisms and autoimmunity: Making the barren field fertile?. Nat Rev Microbiol 2003, 1(2):151.
192. Allan J.S. Public health concerns take center stage in Nuffield Council on Bioethics: A review of animal-to-human transplants: The ethics of xenotransplantation. Sci Eng Ethics 1996, 2(4):486.
193. Barrett A.J. Graft-versus-host disease: A review. J R Soc Med 1987, 80(6):368.
194. Greenstein J.L., White-Scharf M. Xenotransplantation: A review of current issues. J Biolaw Bus 1998, 2(1):46.
195. Heeger P.S. T-cell allorecognition and transplant rejection: A summary and update. Am J Transplant 2003, 3(5):525.
196. Iannone R., Davies S.M. Tissue typing for hematopoietic cell transplantation: Newer techniques and newer antigens for which cross-matching is helpful. Pediatr Transplant 2005, 9(Suppl 7):76.
197. Jiang S., Herrera O., Lechler R.I. New spectrum of allorecognition pathways: Implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004, 16(5):550.
198. Lechler R.I., Sykes M., Thomson A.W., Turka L.A. Organ transplantation-how much of the promise has been realized?. Nat Med 2005, 11(6):605.
199. Martins A.A., Paiva A., Morgado J.M., et al. Quantification and immunophenotypic characterization of bone marrow and umbilical cord blood mesenchymal stem cells by multicolor flow cytometry. Transplant Proc 2009, 41(3):943.
200. Patience C., Takeuchi Y., Weiss R.A. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997, 3(3):282.
201. Rocha P.N., Plumb T.J., Crowley S.D., et al. Effector mechanisms in transplant rejection. Immunol Rev 2003, 196:51.
202. Rogers N.J., Lechler R.I. Allorecognition. Am J Transplant 2001, 1(2):97.
203. Sayegh M.H., Carpenter C.B. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 2004, 351(26):2761.
204. Steels E., Meuleman N., Vereecken P., et al. Graft-versus-host disease: Review of 22 cases. Acta Clin Belg 2004, 59(4):182.
205. Ackerman A.L., Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004, 5(7):678.
206. Brigl M., Brenner M.B. CD1: Antigen presentation and T cell function. Annu Rev Immunol 2004, 22:817.
207. Freigang S., Egger D., Bienz K., et al. Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming. Proc Natl Acad Sci U S A 2003, 100(23):13477.
208. Heath W.R., Carbone F.R. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 2001, 1(2):126.
209. Hewitt E.W. The MHC class I antigen presentation pathway: Strategies for viral immune evasion. Immunology 2003, 110(2):163.
210. Lehner P.J., Trowsdale J. Antigen presentation: Coming out gracefully. Curr Biol 1998, 8(17):R605.
211. Pamer E., Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998, 16:323.
212. Rock K.L., York I.A., Goldberg A.L. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004, 5(7):670.
213. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat Immunol 2004, 5(7):685.
214. Ampel N.M. Coccidioidomycosis: A review of recent advances. Clin Chest Med 2009, 30(2):241.
215. Britton W.J., Lockwood D.N. Leprosy. Lancet 2004, 363(9416):1209.
216. Cano M.V., Hajjeh R.A. The epidemiology of histoplasmosis: A review. Semin Respir Infect 2001, 16(2):109.
217. Casanova J.L., Abel L. Genetic dissection of immunity to mycobacteria: The human model. Annu Rev Immunol 2002, 20:581.
218. Ciclitira P.J., King A.L., Fraser J.S. AGA technical review on Celiac Sprue. American Gastroenterological Association. Gastroenterology 2001, 120(6):1526.
219. Cohen J. Nickel sensitivity. JAMA 1972, 222(5):585.
220. Enk A.H., Katz S.I. Contact sensitivity as a model for T-cell activation in skin. J Invest Dermatol 1995, 105(Suppl 1):80S.
221. Flynn J.L., Chan J., Triebold K.J., et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993, 178(6):2249.
222. Girolomoni G., Sebastiani S., Albanesi C., et al. T-cell subpopulations in the development of atopic and contact allergy. Curr Opin Immunol 2001, 13(6):733.
223. Kalish R.S., Wood J.A., LaPorte A. Processing of urushiol (poison ivy) hapten by both endogenous and exogenous pathways for presentation to T cells in vitro. J Clin Invest 1994, 93(5):2039.
224. Mozzanica N., Rizzolo L., Veneroni G., et al. HLA-A, B, C and DR antigens in nickel contact sensitivity. Br J Dermatol 1990, 122(3):309.
225. North R.J., Jung Y.J. Immunity to tuberculosis. Annu Rev Immunol 2004, 22:599.
226. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004, 4(1):1.
227. Toubiana R., Berlan J., Sato H., et al. Three types of mycolic acid from Mycobacterium tuberculosis Brevanne: Implications for structure-function relationships in pathogenesis. J Bacteriol 1979, 139(1):205.
228. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38(9):1261.
229. Wheat L.J. Histoplasmosis: A review for clinicians from non-endemic areas. Mycoses 2006, 49(4):274.
230. Aggarwal B.B. Comparative analysis of the structure and function of TNF-alpha and TNF-beta. Immunol Ser 1992, 56:6.
231. Catalfamo M., Henkart P.A. Perforin and the granule exocytosis cytotoxicity pathway. Curr Opin Immunol 2003, 15(5):522.
232. Dhanrajani P.J. Papillon-Lefevre syndrome: Clinical presentation and a brief review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108(1):1.
233. Dorothee G., Ameyar M., Bettaieb A., et al. Role of Fas and granule exocytosis pathways in tumor-infiltrating T lymphocyte-induced apoptosis of autologous human lung-carcinoma cells. Int J Cancer 2001, 91(6):772.
234. Finke J.H., Rayman P., Hart L., et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: Specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J Immunother Emphasis Tumor Immunol 1994, 15(2):91.
235. Horn M., Stutte H.J., Schlote W. Familial erythrophagocytic lymphohistiocytosis (Farquhar's disease): Involvement of the central nervous system. Clin Neuropathol 2002, 21(4):139.
236. Lieberman J. The ABCs of granule-mediated cytotoxicity: New weapons in the arsenal. Nat Rev Immunol 2003, 3(5):361.
237. Lord S.J., Rajotte R.V., Korbutt G.S., et al. Granzyme B: A natural born killer. Immunol Rev 2003, 193:31.
238. Lowin B., Peitsch M.C., Tschopp J. Perforin and granzymes: Crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol 1995, 198:1.
239. Loy T.S., Diaz-Arias A.A., Perry M.C. Familial erythrophagocytic lymphohistiocytosis. Semin Oncol 1991, 18(1):34.
240. MacArthur G.J., Wilson A.D., Birchall M.A., et al. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells. J Virol 2007, 81(9):4766.
241. Melief C.J. Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: Peaceful coexistence of cross-priming and direct priming?. Eur J Immunol 2003, 33(10):2645.
242. Merlo A., Turrini R., Bobisse S., et al. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol 2004, 184(10):5895-5902.
243. Oren H., Ozkal S., Gülen H., et al. Autoimmune lymphoproliferative syndrome: Report of two cases and review of the literature. Ann Hematol 2002, 81(11):651.
244. Peters P.J., Borst J., Oorschot V., et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 1991, 173(5):1099.
245. Revell P.A., Grossman W.J., Thomas D.A., et al. Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions. J Immunol 2005, 174(4):2124.
246. Ruddle N.H. Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta). Curr Opin Immunol 1992, 4(3):327.
247. Wong P., Pamer E.G. CD8 T cell responses to infectious pathogens. Annu Rev Immunol 2003, 21:29.
248. Zaidi N., Kalbacher H., Cathepsin E. A mini review. Biochem Biophys Res Commun 2008, 367(3):517.
249. Chung K.F. Individual cytokines contributing to asthma pathophysiology: Valid targets for asthma therapy?. Curr Opin Investig Drugs 2003, 4(11):1320.
250. Colonna M., Borsellino G., Falco M., et al. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 1993, 90(24):12000.
251. Dorak M.T. Role of natural killer cells and killer immunoglobulin-like receptor polymorphisms: Association of HLA and KIRs. Methods Mol Med 2007, 134:123.
252. Falk C.S., Steinle A., Schendel D.J. Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells. J Exp Med 1995, 182(4):1005.
253. Katz P., Zaytoun A.M., Fauci A.S. Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. J Clin Invest 1982, 69(6):1231.
254. Kawano T., Cui J., Koezuka Y., et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A 1998, 95(10):5690.
255. O'Callaghan C.A. Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells. Clin Sci (Lond) 2000, 99(1):9.
256. Perussia B. Lymphokine-activated killer cells, natural killer cells and cytokines. Curr Opin Immunol 1991, 3(1):49.
257. Sankhla S.K., Nadkarni J.S., Bhagwati S.N. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 1996, 27(2):133.
258. Sullivan L.C., Clements C.S., Beddoe T. The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity 2007, 27(6):900.
259. Valteau-Couanet D., Leboulaire C., Maincent K., et al. Dendritic cells for NK/LAK activation: Rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002, 100(7):2554.
260. Wingender G., Kronenberg M. Role of NKT cells in the digestive system. IV. The role of canonical natural killer T cells in mucosal immunity and inflammation. Am J Physiol Gastrointest Liver Physiol 2008, 294(1):1.
261. Winter C.C., Long E.O. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol 1997, 158(9):4026.
262. Yang G., Volk A., Petley T., et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004, 28(6):224.
263. Bennett C.L., Ochs H.D. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr 2001, 13(6):533.
264. Chess L., Jiang H. Resurrecting CD8+ suppressor T cells. Nat Immunol 2004, 5(5):469.
265. Cohn M. The concept of functional idiotype network for immune regulation mocks all and comforts none. Ann Inst Pasteur Immunol 1986, 137(1):64.
266. Cottrez F., Groux H. Specialization in tolerance: Innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells. Transplantation 2004, 77(Suppl 1):S12.
267. Fehervari Z., Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004, 114(9):1209.
268. Hamad A.R., Schneck J.P. Activation-induced T cell death is regulated by CD4 expression. Int Rev Immunol 2001, 20(5):535.
269. Hori S., Sakaguchi S. Foxp3: A critical regulator of the development and function of regulatory T cells. Microbes Infect 2004, 6(8):745.
270. Jiang H., Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004, 114(9):1198.
271. Papiernik M. Natural CD4+ CD25+ regulatory T cells. Their role in the control of superantigen responses. Immunol Rev 2001, 182:180.
272. Satthaporn S., Eremin O. Dendritic cells (I): Biological functions. J R Coll Surg Edinb 2001, 46(1):9.
273. Tung K.S. Human sperm antigens and antisperm antibodies I, Studies on vasectomy patients. Clin Exp Immunol 1975, 20(1):93.
274. Arlen P.M., Skarupa L., Pazdur M., et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007, 178(4 Pt 1):1515.
275. Belli F., Testori A., Rivoltini L., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. J Clin Oncol 2002, 20(20):4169.
276. Coulie P.G., Karanikas V., Lurquin C., et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002, 188:33.
277. de Gruijl T.D., van den Eertwegh A.J., Pinedo H.M., et al. Whole-cell cancer vaccination: From autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008, 57(10):1569.
278. Kao J.Y., Zhang M., Chen C.M., et al. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett 2005, 101(2):154.
279. Klein G. The strange road to the tumor-specific transplantation antigens (TSTAs). Cancer Immun 2001, 1:6.
280. Murthy V., Moiyadi A., Sawant R., et al. Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer. Curr Mol Med 2009, 9(6):725.
281. Nesslinger N.J., Ng A., Tsang K.Y., et al. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res 2009, 16(15):4046.
282. Ovali E., Dikmen T., Sonmez M., et al. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: A safety study. J Exp Clin Cancer Res 2007, 26(2):209.
283. Patel P.H., Kockler D.R., Sipuleucel T. A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008, 42(1):91.
284. Ruffini P.A., Neelapu S.S., Kwak L.W., et al. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: From prototype protein to second generation vaccines. Haematologica 2002, 87(9):989.
285. Saenz-Badillos J., Amin S.P., Granstein R.D. RNA as a tumor vaccine: A review of the literature. Exp Dermatol 2001, 10(3):143.
286. Scanlan M.J., Gordon C.M., Williamson B., et al. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002, 98(4):485.
287. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002, 20:395.
288. Toh H.C., Wang W.W., Chia W.K., et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin Cancer Res 2009, 15(24):7726.
289. Agren L., Lowenadler B., Lycke N. A novel concept in mucosal adjuvanticity: The CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol Cell Biol 1998, 76(3):280.
290. Audibert F.M., Lise L.D. Adjuvants: Current status, clinical perspectives and future prospects. Immunol Today 1993, 14(6):281.
291. Curtiss R. Bacterial infectious disease control by vaccine development. J Clin Invest 2002, 110(8):1061.
292. Eldridge J.H., Staas J.K., Meulbroek J.A., et al. Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991, 28(3):287.
293. Fine P.E. Herd immunity: History, theory, practice. Epidemiol Rev 1993, 15(2):265.
294. Gagnon R., Primeau M.N., Des Roches A., et al. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2007, 126(2):317.
295. Herman J.J., Radin R., Schneiderman R. Allergic reactions to measles (rubeola) vaccine in patients hypersensitive to egg protein. J Pediatr 1983, 102(2):196.
296. James J.M., Zeiger R.S., Lester M.R., et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998, 133(5):624.
297. Kelso J.M., Jones R.T., Yunginger A.W. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol 1993, 91(4):867.
298. Kotani S., Watanabe Y., Kinoshita F., et al. Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids. Biken J 1975, 18(2):105.
299. Neutra M.R., Kozlowski P.A. Mucosal vaccines: The promise and the challenge. Nat Rev Immunol 2006, 6(2):148.
300. Petrovsky N., Aguilar J.C. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 2004, 82(5):488.
301. Pichichero M.E., Badgett J.T., Rodgers G.C., et al. Acellular pertussis vaccine: Immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. Pediatr Infect Dis J 1987, 6(4):352.
302. Russell M., Pool V., Kelso J.M., et al. Vaccination of persons allergic to latex: A review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004, 23(5):664.
303. Singer S., Johnson C.E., Mohr R., et al. Urticaria following varicella vaccine associated with gelatin allergy. Vaccine 2004, 17(4):327.
304. Snider D.P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit Rev Immunol 1995, 15(3-4):317.
305. Souza A.R., Braga J.A., de Paiva T.M., et al. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia. Vaccine 2010, 28(4):1117.
306. Storm G. Liposome advances. Sixth International Conference. Progress in drug and vaccine delivery. IDrugs 2004, 7(2):122.
307. van der Lubben I.M., Verhoef J.C., Borchard G., et al. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 2001, 14(3):201.
308. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization 1994, 12(5):387.
309. Williams A.N., Woessner K.M. Monosodium glutamate "allergy": Menace or myth?. Clin Exp Allergy 2009, 39(5):640.
310. Worm M., Sterry W., Zuberbier T. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Derm Venereol 2000, 80(3):232.
311. Zinkernagel R.M. On natural and artificial vaccinations. Annu Rev Immunol 2003, 21:515.
312. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine preventable diseases 2007, Public Health Foundation, Washington, DC. ed 10. W. Atkinson, J. Hambrosky, L. McIntyre (Eds.).
313. Bellini W.J., Rota J.S., Lowe L.E., et al. Subacute sclerosing panencephalitis: More cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005, 192(10):686.
314. Belshe R.B., Mendelman P.M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998, 338(20):1405.
315. Centers for Disease Control and Prevention A comprehensive immunization strategy to eliminate transmission of hepatitis infections in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005, 54(No. RR-16):1.
316. Centers for Disease Control and Prevention Haemophilus type b conjugate vaccine for prevention of Haemophilus type b among children two months of age and older: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991, 40(No. RR-1):1.
317. Centers for Disease Control and Prevention Measles, mumps and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998, 47(No. RR-8):1.
318. Centers for Disease Control and Prevention Poliomyelitis prevention in the United States: Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000, 49(No. RR-5):1.
319. Centers for Disease Control and Prevention Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005, 54(No. RR-7):1.
320. Centers for Disease Control and Prevention Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 52(No. RR-x):1155.
321. Centers for Disease Control and Prevention Preventing tetanus, diphtheria and pertussis among adolescents: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 55(No. RR-3):1.
322. Centers for Disease Control and Prevention Prevention of rotavirus gastroenteritis among infants and children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 55(No. RR-12):1.
323. Centers for Disease Control and Prevention Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996, 45(No RR-6):1.
324. Freed G.L., Konrad T.R., DeFriese G.H., Lohr J.A. Adoption of a new Haemophilus influenzae type b vaccine recommendation. Am J Dis Child 1993, 147(2):124.
325. Halperin S.A. Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: Reassurance for the future. J Pediatr 2006, 149(5):589.
326. Juskewitch J.E., Tapia C.J., Windebank A.J. Lessons from the Salk polio vaccine: Methods for and risks of rapid translation. Clin Transl Sci 2010, 3(4):182.
327. Koopman J.S., Monto A.S. The Tecumseh Study. XV: Rotavirus infection and pathogenicity. Am J Epidemiol 1989, 130(4):750.
328. Kretsinger K., Broder K.R., Cortese M.M., et al. Preventing tetanus, diphtheria, and pertussis among adults: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of DTaP among health-care personnel. MMWR Recomm Rep 2006, 55(RR-17):1.
329. Mellinger A.K., Cragan J.D., Atkinson W.L., et al. High incidence of congenital rubella syndrome after a rubella outbreak. Pediatr Infect Dis J 1995, 14(7):573.
330. Moxon E.R., Vaughn K.A. The type b capsular polysaccharide as a virulence determinant of Haemophilus influenzae: Studies using clinical isolates and laboratory transformants. J Infect Dis 1981, 143(4):517.
331. Murphy T.V., Gargiullo P.M., Massoudi M.S., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344(8):564.
332. Poland G.A., Jacobson R.M. Clinical practice: Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004, 351(27):2832.
333. Rosenstein N.E., Perkins B.A., Stephens D.S., et al. Meningococcal disease. N Engl J Med 2001, 344(18):1378.
334. Seward J.F., Watson B.M., Peterson C.L., et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002, 287(5):606.
335. Smith D.R., Leggat P.A. Pioneering figures in medicine: Albert Bruce Sabin-inventor of the oral polio vaccine. Kurume Med J 2005, 52(3):111.
336. Sukupolvi-Petty S., Grass S., St Geme J.W. The Haemophilus influenzae type b hcsA and hcsB gene products facilitate transport of capsular polysaccharide across the outer membrane and are essential for virulence. J Bacteriol 2006, 188(11):3870.
337. Whitney C.G. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults ages. Geriatrics 2003, 58(10):20.
338. Altfeld M., Allen T.M., Yu X.G., et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002, 420(6914):434.
339. Anonymous: Revised surveillance case definitions for HIV infections among adults and children ?18 months and for HIV infection and AIDS among children aged 18 months to ?13 years. Recommendations and Reports. Appendix A. MMWR 2008, 57(RR10):9.
340. Day C.L., Walker B.D. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 2003, 198(12):1773.
341. Douek D.C., Picker L.J., Koup R.A. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003, 21:265.
342. Gao F., Bailes E., Robertson D.L., et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999, 397(6718):436.
343. Jaffar S., Hall A.J. Disease progression in HIV-1 or HIV-2-infected individuals of West African origin resident in the West. AIDS 1997, 11(11):1398.
344. Keele B.F., Van Heuverswyn F., Li Y., et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313(5786):523.
345. Lemey P., Pybus O.G., Wang B., et al. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A 2003, 100(11):6588.
346. Levy J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993, 57(1):183.
347. Muller-Trutwin M.C., Corbet S., Souquière S., et al. SIVcpz from a naturally infected Cameroonian chimpanzee: Biological and genetic comparison with HIV-1N. J Med Primatol 2000, 29(3-4):166.
348. Noireau F. HIV transmission from monkey to man. Lancet 1987, 1(8548):1498.
349. Ochsenbein A.F., Riddell S.R., Brown M., et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med 2004, 200(11):1407.
350. Piot P., Feachem R.G., Lee J.W., et al. Public health. A global response to AIDS: Lessons learned, next steps. Science 2004, 304(5679).
351. Rollman E., Smith M.Z., Brooks A.G., et al. Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: Implications for HIV vaccine strategies. J Immunol 2007, 179(7):4571.
352. Salerno-Goncalves R., Lu W., Achour A., et al. HLA-unrestricted killing of HIV-1 gag protein-expressing CD4 T cells by gag-specific CD8 cytotoxic T cells. AIDS 1999, 13(12):1583.
353. Stebbing J., Moyle G. The clades of HIV: Their origins and clinical significance. AIDS Rev 2003, 5(4):205.